Nasdaq
$7.81▼ 0.45%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $83.8MShares out 10.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
38- 10.2Regular26.10.03 04:56SCHEDULE 13G/AOwnership#●●●#●●●
KAZIA THERAPEUTICS LTD
Dauntless Investment Group, LLC has filed a Schedule 13G/A amendment regarding its beneficial ownership in Kazia Therapeutics Ltd. The filing serves as an official update to the investor's stake in the company.…more
$7.81-0.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.22Pre-market26.09.22 21:04424B3Offering
KAZIA THERAPEUTICS LTD
Final prospectus filed (supplement format).
$7.81-0.45%vs prev closeView filingShare - 9.22Pre-market26.09.22 21:03424B3Offering
KAZIA THERAPEUTICS LTD
Final prospectus filed (supplement format).
$7.81-0.45%vs prev closeView filingShare
37 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.22Pre-market26.09.22 20:33#●●●#●●●
Kazia Therapeutics Announces First Patient Dosed in Paxalisib Epilepsy Trial…more
Kazia Therapeutics' partner, Sovargen, has initiated dosing for the first patient in a Phase 1b/2a clinical trial of paxalisib for intractable epilepsy. This milestone triggers a $2 million payment to Kazia under their existing licensing agreement.…more
$7.81-0.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.9Pre-market26.09.09 20:32
●●●●●●●● ●●●●● ●●●●●●
Kazia Therapeutics has initiated dosing for the first patient in a Phase 2 study evaluating paxalisib in combination with gemcitabine for AT/RT. This trial aims to address one of the most aggressive forms of pediatric brain cancer.…more
$7.81-0.45%vs prev closeShareBenzinga - 9.1Pre-market26.09.01 20:33
●●●●●●●● ●●●●● ●●●●●●
Kazia Therapeutics reported that its lead drug candidate, paxalisib, reduced tumor burden by 52% in a preclinical model of colorectal cancer. The company is now preparing to initiate a Phase 2 clinical study targeting immunotherapy-resistant colorectal cancer patients.…more
$7.81-0.45%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report